Alliance -

Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
An investigation of both clinical and pharmacogenetic risk factors for bevacizumab-related gastrointestinal hemorrhage, which was collected prospectively from a large, randomized phase III trial. - The Pharmacogenomics Journal
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk (AFT-29)
A post hoc analysis of patients with newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities who are transplant-eligible. - The Blood Cancer Journal

Phase 2 and 3 transplant-eligible NDMM data build evidence for quadruplet therapy
The first in a two-part series on trials in transplant-eligible newly diagnosed multiple myeloma that includes AFT-29 (GRIFFIN). - Targeted Onology

Improving rural clinical trial enrollment: recommendations from the Rural Health Working Group of the Alliance Clinical Trials Network
A look at how to improve the clinical infrastructure to encourage enrollment of rural populations through system-level changes. - Journal of Clinical Oncology

Secondary primary lung cancer rates similar in early NSCLC regardless of resection type
A secondary analysis of CALGB 140503 – a non-small cell lung cancer trial. - Cancer Network

Natera and Alliance for Clinical Trials in Oncology announce activation of Alliance A032103 (MODERN): A randomized, phase II/III adjuvant trial in urothelial cancer
A trial with both escalation and de-escalation arms for patients in muscle-invasive urothelial cancer has recently opened - Alliance A032103 (MODERN). - Business Wire